WOBURN, Mass., Feb. 07, 2025 (GLOBE NEWSWIRE) -- Replimune Group, Inc. (NASDAQ: REPL), a clinical stage biotechnology company pioneering the development of novel oncolytic immunotherapies, today announced the grant of inducement equity awards to newly hired non-executive employees.
Replimune Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Seeking Alpha / 1 hour from now 1 Views
Comments